目的:探讨艾司洛尔对未行紧急再灌注治疗的急性ST段抬高型心肌梗死患者的临床疗效。方法:选择各种原因未能行紧急再灌注治疗的急性ST段抬高型心肌梗死患者70例,随机对照组(35例)和艾司洛尔组(35例);观察两组治疗前后的临床效果、心功能指标并评估其安全性。结果:艾司洛尔组缓解缺血性胸痛及降低抬高的ST段明显优于对照组(P〈0.05);治疗后艾司洛尔组心率、脑纳素(BNP)、左室收缩末期内径(LVEDD)明显低于对照组(P〈0.05);左室射血分数(LVEF)明显高于对照组(P〈0.05)。结论:艾司洛尔对未行紧急再灌注治疗的急性ST段抬高型心肌梗死患者能显著缓解缺血性胸痛,明显改善患者心功能,不良反应少,安全有效。
Objective:To observe the clinical effect of esmolol in the treatment for patients with ST ele- vation myocardial infarction, who did not undergo directly percutaneous coronary intervention. Methods: Seventy cases of ST elevation myocardial infarction, who did not undergo directly per- cutaneous coronary intervention were randomly divided into two groups, esmolol group (n=35) and control group (n=35). Results: The clinical effect in esmolol group were significantly im- proved than those in control group (P〈0.05). The HR, BNP and the LVEDD in esmolol group were significantly lower than those in control group (P〈0.05). The LVEF in esmolol group were significantly higher than those in control group (P〈0.05). Conclusion: The intravenous in- jection of esmolol is a safe and effective treatment strategy for treating patients with ST elevation myocardial infarction, who did not undergo directly percutaneous coronary intervention.